Promoter methylation of glutathione S-transferase π1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression

Cancer

Volumn 115, Issue 14, 2009, Pages 3222-3232

  Gao, Peng ^a   Yang, Xi ^b   Xue, Yu Wen ^b   Zhang, Xiao Fang ^a   Wang, Yan ^a   Liu, Wen Jun ^a   Wu, Xiao Juan ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Bronchioloalveolar carcinoma; DNA methyltransferase 1; Glutathione S transferase 1; Methylation; Prognosis

Indexed keywords

DNA METHYLTRANSFERASE 1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE P1; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; LUNG RESECTION; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METHYLATION; TUMOR LOCALIZATION; TUMOR RECURRENCE; TUMOR VOLUME;

ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; DISEASE PROGRESSION; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; PROMOTER REGIONS, GENETIC;

EID: 68549126939     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24369     Document Type: Article

References (38)

1. Colby TV, Koss M, Travis MD. Tumors of the Lower Respiratory Tract. 3rd ed. Washington, DC: Armed Forces Institute of Pathology; 1995.
2. Travis WD, Colby TV, Corrin B, Shinmosato Y, Brambilla E; In collaboration with Sobin LH and pathologists from 14 countries. Histologic Typing of Lung and Pleural Tumours. WHO International Histological Classification of Tumors. 3rd ed. Berlin, Germany: Springer; 1999.
3. Terasaki H, Niki T, Matsuno Y, et al. Lung adenocarcinoma with mixed bronchioloalveolar and invasive components: clinicopathological features, subclassification by extent of invasive foci, and immunohistochemical characterization. Am J Surg Pathol. 2003;27:937-951. (Pubitemid 36758897)
4. Noguchi M, Morikawa A, Kawasaki M, et al. Small adenocarcinoma of the lung. Histologic characteristics and prognosis. Cancer. 1995;75:2844-2852.
5. Huang Y, Sadee W. Membrane transporters and channels in chemoresistance and -sensitivity of tumor cells. Cancer Lett. 2006;239:168-182. (Pubitemid 43996825)
6. Jakoby WB. The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol. 1978;46:383-414.
7. Marchetti S, Mazzanti R, Beijnen JH, Schellens JH. Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007;12:927-941. (Pubitemid 47359135)
8. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K. Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S- transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest. 2008;26:344-351. (Pubitemid 351601390)
9. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol. 1995;30:445-600. (Pubitemid 26016466)
10. Marie JP, Legrand O. MDR1/P-GP expression as a prognostic factor in acute leukemias. Adv Exp Med Biol. 1999;457:1-9. (Pubitemid 129735292)
11. Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res. 2000;6:4618-4627. (Pubitemid 32110396)
12. Ellinger J, Bastian PJ, Jurgan T, et al. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. Urology. 2008;71:161-167. (Pubitemid 351173282)
13. Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, Trucco G. Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett. 2007;257:136-144. (Pubitemid 47464705)
14. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-428.
15. Garinis GA, Patrinos GP, Spanakis NE, Menounos PG. DNA hypermethylation: when tumour suppressor genes go silent. Hum Genet. 2002;111:115-127.
16. Arora P, Kim EO, Jung JK, Jang KL. Hepatitis C virus core protein down-regulates E-cadherin expression via activation of DNA methyltransferase 1 and 3b. Cancer Lett. 2008;261:244-252.
17. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19:219-220. (Pubitemid 28309328)
18. Bestor TH. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J. 1992;11:2611-2617.
19. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552-556. (Pubitemid 34288859)
20. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61:3419-3424.
21. Hsu HS, Wang YC, Tseng RC, et al. 5'-Cytosine-phosphoguanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 over-expression in resected non-small cell lung cancer. Clin Cancer Res. 2004;10:4734-4741.
22. Lin RK, Hsu HS, Chang JW, Chen CY, Chen JT, Wang YC. Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer. 2007;55:205-213.
23. Jaffe ES, Harris NL, Stein H, Vardiman JV, eds. World Health Organization Classification of Tumours. Lyon, France: IARC Press; 2004.
24. Corn PG, Heath EI, Heitmiller R, et al. Frequent hypermethylation of the 5 CpG island of E-cadherin in esophageal adenocarcinoma. Clin Cancer Res. 2001;7:2765-2769. (Pubitemid 32911382)
25. Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol. 2004;164:689-699. (Pubitemid 38364682)
26. Kuo TH, Liu FY, Chuang CY, Wu HS, Wang JJ, Kao A. To predict response chemotherapy using technetium-99m tetrofosmin chest images in patients with untreated small cell lung cancer and compare with P-glycoprotein, multidrug resistance related protein-1, and lung resistance-related protein expression. Nucl Med Biol. 2003;30:627-632. (Pubitemid 37289324)
27. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S. Association of GSTP1 CpG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat. 2006;100:169-176. (Pubitemid 44631918)
28. Lee JS. GSTP1 promoter hypermethylation is an early event in breast carcinogenesis. Virchows Arch. 2007;450: 637-642.
29. Chandra RK, Bentz BG, Haines GK 3rd, Robinson AM, Radosevich JA. Expression of glutathione S-transferase pi in benign mucosa, Barrett's metaplasia, and adenocarcinoma of the esophagus. Head Neck. 2002;24:575-581.
30. Bastian PJ, Palapattu GS, Yegnasubramanian S, et al. CpG island hypermethylation profile in the serum of men with clinically localized and hormone refractory metastatic prostate cancer. J Urol. 2008;179:529-534.
31. Yasui K, Mihara S, Zhao C, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403-1410. (Pubitemid 38235609)
32. Kuwano M, Uchiumi T, Hayakawa H, et al. The basic and clinical implications of ABC transporters, Y-box-binding protein-1 (YB-1) and angiogenesis-related factors in human malignancies. Cancer Sci. 2003;94:9-14.
33. Baker EK, Johnstone RW, Zalcberg JR, El-Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. Oncogene. 2005;24:8061-8075. (Pubitemid 41746749)
34. Tsang WP, Kwok TT. Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene. 2007;26:4877-4881.
35. Enokida H, Shiina H, Igawa M, et al. CpG hypermethylation ofMDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res. 2004;64:5956-5962. (Pubitemid 39129391)
36. Qiu YY, Mirkin BL, Dwivedi RS. MDR1 hypermethylation contributes to the progression of neuroblastoma. Mol Cell Biochem. 2007;301:131-135.
37. Kim H, Kwon YM, Kim JS, et al. Elevated mRNA levels of DNA methyltransferase-1 as an independent prognostic factor in primary nonsmall cell lung cancer. Cancer. 2006;107:1042-1049. (Pubitemid 44291153)
38. Kwon YM, Park JH, Kim H, et al. Different susceptibility of increased DNMT1 expression by exposure to tobacco smoke according to histology in primary nonsmall cell lung cancer. J Cancer Res Clin Oncol. 2007; 133:219-226. (Pubitemid 46255012)